MDS

Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.

Cecilia BrownMyelodysplastic Syndromes | September 14, 2023
The proof-of-concept study showed that noninvasive hemoglobin measurement is “feasible,” but there were several ...
Read More
Cecilia BrownMeeting News | September 14, 2023
One aim is to evaluate the efficacy of oral decitabine/cedazuridine and magrolimab in intermediate to HR MDS.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | September 14, 2023
Joseph Khoury, MD; Sanam Loghavi, MD; and Chadi Nabhan, MD, MBA, FACP, discuss the MDS classification systems.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 13, 2023
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Rami Komrokji, MDVideo Insights | September 10, 2023
Dr. Komrokji speaks about what might follow the recent FDA approval of luspatercept for certain patients with MDS.
Cecilia BrownMeeting News | September 9, 2023
Researchers sought to differentiate the mechanism of action of luspatercept from epoetin alfa.
Robert Hasserjian, MDMeeting News | September 9, 2023
Dr. Hasserjian discusses a presentation about the classification system that he gave at the SOHO Annual Meeting.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 9, 2023
A research team sought in their study to determine if the IPSS-M could also apply to CMML.
Phillip Scheinberg, MDMyelodysplastic Syndromes | September 8, 2023
"There's been a lot of focus on classifications and mutations: they're coming with a lot of force," Dr. Scheinberg said.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 8, 2023
Dr. Platzbecker joins Chadi Nabhan, MD, MBA, FACP, to discuss MDS at the Eleventh Annual Meeting of SOHO.
Guillermo Garcia-Manero, MDMeeting News | September 7, 2023
Guillermo Garcia-Manero, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss the COMMANDS trial at the SOHO Annual Meeting.
Blood Cancers Today Staff WritersMeeting News | September 6, 2023
Allogeneic HSCT can yield favorable outcomes in treating patients with therapy-related MDS.
Blood Cancers Today Staff WritersMeeting News | September 5, 2023
A presentation by Dr. Rami Komrokji at the Eleventh SOHO Annual Meeting gave additional insights into the COMMANDS trial.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 5, 2023
Luspatercept is highly effective in treating ESA-naïve patients with LR-MDS.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | September 1, 2023
Response rates were high, and OS was improved in patients receiving venetoclax, although not statistically significant.
Cecilia BrownMyelodysplastic Syndromes | August 29, 2023
The expanded indication to the frontline setting is based on interim results from the pivotal phase III COMMANDS trial.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | August 4, 2023
Guillermo Garcia-Manero, MD, the 2023 SOHO President-Elect, shares his hopes and goals for the coming years.
Cecilia BrownMyelodysplastic Syndromes | July 26, 2023
The study's authors found evidence showing that "heme might serve as a rheostat directing cells to live or die."
Cecilia BrownMyelodysplastic Syndromes | July 25, 2023
Gilead Sciences, Inc, the manufacturer of the drug, recommends discontinuing magrolimab treatment in patients with MDS.
Cecilia BrownMyelodysplastic Syndromes | July 24, 2023
The single-center phase I/II study evaluated the triplet combination after hypomethylating agent failure.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Leah SherwoodMyelodysplastic Syndromes | July 7, 2023
The FDA has removed the partial clinical hold on the TakeAim Leukemia phase I/II study of emavusertib. 
Cecilia BrownMyelodysplastic Syndromes | July 7, 2023
The study compared luspatercept with epoetin alfa in patients with lower-risk MDS who were naive to ESA treatment.
Leah SherwoodMyelodysplastic Syndromes | June 26, 2023
An NDA for the telomerase inhibitor imetelstat has been submitted to the FDA.
Cecilia BrownVideo Insights | June 13, 2023
Dr. Winer discusses emavusertib, an orally bioavailable, reversible inhibitor of IRAK4.
Cecilia BrownMeeting News | June 13, 2023
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Cecilia BrownMyelodysplastic Syndromes | June 13, 2023
The median OS was 13.3 months in patients receiving CPX-351, while it was 11.4 months in those receiving FLAG-Ida.
Cecilia BrownMyelodysplastic Syndromes | June 13, 2023
In the 84 patients with MDS who were identified as vulnerable, 88% had difficulty with prolonged physical activity.
Cecilia BrownMyelodysplastic Syndromes | June 13, 2023
The investigators replicated the statistical plan of the MEDALIST trial to evaluate luspatercept outside of a clinical trial.
Leah SherwoodMyelodysplastic Syndromes | June 12, 2023
KER-050 is a modified activin receptor type IIA ligand trap designed to inhibit select TGF-β superfamily ligands.
Leah SherwoodMeeting News | June 12, 2023
The study evaluated imetelstat versus placebo in patients with lower-risk MDS who were highly transfusion dependent.
Leah SherwoodMeeting News | June 11, 2023
Dr. Stéphane De Botton discusses his EHA abstract on tamibarotene-based therapy in MDS/AML.
Guillermo Garcia-Manero, MDVideo Insights | June 9, 2023
Dr. Garcia-Manero presented results from the phase III COMMANDS trial during the 2023 ASCO Meeting.
Cecilia BrownMyelodysplastic Syndromes | June 6, 2023
Most patients (82%) had a low transfusion burden at baseline.
Cecilia BrownMyelodysplastic Syndromes | June 5, 2023
A subset of TP53-mutated myeloid neoplasms, such as MDS, are preceded by TP53-mutated CCUS.
Cecilia BrownMyelodysplastic Syndromes | June 5, 2023
Nearly one-third (29%) of patients were upstaged from their IPSS-R score by the IPSS-M.
Cecilia BrownMyelodysplastic Syndromes | June 4, 2023
Dr. Garcia-Manero presented information about a phase Ib study of IRAK1/4 inhibition at the 2023 ASCO Annual Meeting.
Cecilia BrownMeeting News | June 3, 2023
In this video, Dr. Garcia-Manero discusses the study's primary endpoint, its implications for patients, and more.
Cecilia BrownMeeting News | June 2, 2023
Dr. Zeidan speaks about the rationale behind the trial, the implications of its results, and the next steps.
Leah SherwoodMyelodysplastic Syndromes | May 11, 2023
The field of hematologic oncology is now contending with reconciling the proposed rival WHO and ICC systems.
Leah SherwoodMyelodysplastic Syndromes | May 11, 2023
The Type II Variation Application was accepted by the European Medicines Agency (EMA) as well.
Cecilia BrownMyelodysplastic Syndromes | May 8, 2023
Dr. Zeidan discusses a patient who shaped his career path, the pressing questions in MDS and AML, and more.
Cecilia BrownMyelodysplastic Syndromes | May 4, 2023
Certain cellular pathways were upregulated in patients with myelodysplastic syndromes (MDS) who responded to immunotherapy.
Cecilia BrownMyelodysplastic Syndromes | May 3, 2023
Researchers retrospectively screened patients with VEXAS for clonal hematopoiesis in their peripheral blood.
Cecilia BrownMyelodysplastic Syndromes | May 3, 2023
The study assessed “patterns of consideration” for HSCT and identified factors associated with transplant referral rates.
Cecilia BrownMyelodysplastic Syndromes | May 2, 2023
The study showed starting statin therapy at MDS diagnosis was associated with a 38% improvement in OS.
Leah LawrenceMyelodysplastic Syndromes | April 12, 2023
Novel targets are under investigation in several types of hematologic malignancies.
Cecilia BrownMyelodysplastic Syndromes | April 12, 2023
The ICC and WHO both “proposed significant changes” to the diagnostic criteria for MDS in 2022.
Cecilia BrownMyelodysplastic Syndromes | April 7, 2023
In patients with TP53 mutations, 40% achieved a complete response, with a median OS of 16.3 months.
Cecilia BrownMyelodysplastic Syndromes | April 6, 2023
The three-year OS rate was 91.3% for patients who were MRD negative, while it was 66.4% for those who were MRD positive.
Advertisement
Advertisement
Advertisement
Advertisement
Latest News

September 22, 2023